Review of Industrial Organization 22: 85–87, 2003. Book Review The Japanese Pharmaceutical Industry, L. G. Thomas, III. Cheltenham, U.K.: Edward Elgar Publishing, 2001, 232 pages, $80. The story Thomas tells is rather alarming. Early in the 1970s, the United States ex- perienced a well-documented lag in the introduction of new drugs. It took the FDA many years to eliminate that lag. During the past decade such a lag has emerged again – this time in Japan. In this slim volume, Thomas analyzes the nature, causes, and consequences of the new drug lag in Japan, drawing attention to the powerful role of Japanese domestic politics in shaping pharmaceutical practices in that na- tion. According to Thomas, more than 80 percent of the signiﬁcant pharmaceutical innovations in recent years are unavailable in Japan, denying patients the beneﬁts of important new treatments. Thomas focuses attention on innovations that have been approved for use in six or more nations – drugs he terms “global”. He reports that a mere 13 percent of the products that have gained global acceptance since 1995 were available in Japan in 2000. Looking back to 1990, only 33 percent of the products that had gained global acceptance were
Review of Industrial Organization – Springer Journals
Published: Oct 4, 2004
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud